Efficacy News and Research

RSS

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.

23 Oct 2018

Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC

Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.

23 Oct 2018

Researchers receive National Science Foundation grant to create SMS-based virtual health coach

An interdisciplinary group of researchers at the University of Illinois at Chicago has received a grant from the National Science Foundation to create an SMS-based virtual health coach that would help overweight people set and achieve healthy eating and exercise goals.

23 Oct 2018

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

A new program project grant from the National Cancer Institute will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor T cell therapy at fighting solid tumors.

23 Oct 2018

Patient-reported data confirms efficacy of brachytherapy alone in intermediate risk prostate cancer

Oncology trial RTOG 0232 comparing a combined treatment of external beam therapy and brachytherapy to transperineal interstitial permanent brachytherapy alone indicate a significantly different clinician and patient-reported late toxicity profile between arms despite similarities in progression-free survival results.

22 Oct 2018

Study: Targeting specific genomic mutation in breast cancer improves survival

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

22 Oct 2018

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

EUSA Pharma welcomes the news that FOTIVDA (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology clinical practice guidelines for advanced renal cell carcinoma, anticipated to be published at the end of this year.

22 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for KALYDECO (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

22 Oct 2018

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

A high concentration of multi-strain probiotic helps to reduce mild to moderate episodes of chemotherapy-induced diarrhea in cancer patients, according to results of a phase II/III study in India.

22 Oct 2018

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis, Inc. today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC). The findings are being presented this week at the European Society for Medical Oncology 2018 Congress being held October 19-23 in Munich, Germany.

22 Oct 2018

Pilot clinical trial shows effectiveness of bioelectronic medicine device for lupus

A bioelectronic medicine device was effective in reducing pain and fatigue in patients with lupus, according to Feinstein Institute for Medical Research Professor Cynthia Aranow, MD, who will present pilot clinical trial results Tuesday at the American College of Rheumatology/Association of Rheumatology Professional's Annual Meeting.

22 Oct 2018

11th World Stroke Congress examines high stroke impact in low- and middle-income countries

11th World Stroke Congress brings together leading international stroke experts and an unparalleled scientific program covering epidemiology, prevention, acute care, recovery and rehabilitation in 100s of sessions and oral posters.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

22 Oct 2018

Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer

Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich.

22 Oct 2018

Newly discovered compound shows potential for treating Parkinson's disease

A joint research group centered around Professor Hideyuki Okano and Associate Professor Jun Kohyama, Department of Physiology of the Keio University School of Medicine, together with a research group of Eisai Co., Ltd. has identified a compound that has the potential to be a treatment for Parkinson's disease by using dopaminergic neurons differentiated from induced pluripotent stem (iPS) cells from patients with familial Parkinson's disease.

19 Oct 2018

Green filters increase reading speed for children with dyslexia

Reading, one of the most difficult activities for children with dyslexia, can be improved by the use of green filters.

19 Oct 2018

Efficacy News and Research

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC

Researchers receive National Science Foundation grant to create SMS-based virtual health coach

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

Patient-reported data confirms efficacy of brachytherapy alone in intermediate risk prostate cancer

Study: Targeting specific genomic mutation in breast cancer improves survival

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Pilot clinical trial shows effectiveness of bioelectronic medicine device for lupus

11th World Stroke Congress examines high stroke impact in low- and middle-income countries

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer

Newly discovered compound shows potential for treating Parkinson's disease

Green filters increase reading speed for children with dyslexia

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News